Some of the above strategies for managing OA are also aimed at treating synovitis and synovial fibrosis by interfering with e.g. TLR engagement, NLRP3 inflammasome activation, pro-inflammatory cytokines (e.g., TNF-α, IL-1β). This evidence concerns the gene TNF and synovitis.